Cite
HARVARD Citation
Alten, R. et al. (n.d.). THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. Annals of the rheumatic diseases. p. 267. [Online].